CRADA "reasonable pricing" clauses
Sen. Lieberman (D-Conn.) says he will work on reaching an administrative agreement -- or "if not, I'll be prepared to introduce legislation" -- to eliminate the use of "reasonable pricing" clauses in Cooperative Research & Development Agreements between the National Institutes of Health and industry. Lieberman made his opinion of reasonable pricing known during a May 26 Senate Small Business Committee hearing on childhood disease research. Reps. Waxman (D-Calif.) and Wyden (D-Ore.) are working on CRADA legislation ('The Pink Sheet" April 11, p. 3)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth